• Smile Brands Scoops Up Dentistry of Sarasota

    On December 2, Smile Brands, one of the largest providers of dental support services in the United States, announced its new partnership with Dentistry of Sarasota. Financial terms of the deal were not disclosed. Smile Brands provides business support services to general and multi-specialty dental groups since its founding in 1998. The company... Read More »
  • Ingenovis Health to Acquire HealthCare Support

    Ingenovis Health, Inc., one of the fastest-growing providers of healthcare staffing, announced on November 29 that it has agreed to acquire HealthCare Support, a national healthcare staffing platform providing a full range of customized hiring solutions across the country. Financial terms of the transaction, which is expected to close in the... Read More »
  • Edifecs to Acquire Health Fidelity

    On November 22, Edifecs, Inc. announced that it has signed a definitive agreement to acquire Health Fidelity, a leading provider of risk adjustment solutions for the value-based care era. The acquisition is expected to close in mid-December of this year, pending regulatory approval. Founded in 1996, Edifecs is a premier technology company in the... Read More »
  • Israeli Startup TailorMed Acquires Vivor

    On November 29, TailorMed, a leading financial navigation platform that helps healthcare organizations and patients remove financial barriers to care, announced that it has acquired Vivor, a financial assistance technology platform for healthcare providers and life sciences. The financial terms of the transaction were not disclosed. TailorMed is... Read More »
  • HomeCentris Healthcare Acquires Grace Home Healthcare

    On November 26, HomeCentris Healthcare, LLC announced that it had acquired Grace Home Healthcare, LLC. The deal was closed in October for an undisclosed amount. Headquartered in Owings Mills, Maryland, HomeCentris Healthcare, LLC is an independent home and community-based care organization. It was founded in 2000 and provides its services to... Read More »
AzurRz BioPharma Acquires First Wave Bio

AzurRz BioPharma Acquires First Wave Bio

AzurRz BioPharma, Inc., a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced that it has entered into a definitive agreement to acquire First Wave Bio, Inc. in a stock and cash transaction valued at $229 million. H.C. Wainwright & Co. acted as advisor to AzurRx in connection with the acquisition. Founded in 2015, First Wave Bio, Inc. is a clinical-stage biotechnology company specializing in the development of novel, gut-targeted, small molecule therapies for the treatment of auto-immune inflammatory bowel diseases (IBD) and other serious conditions. AzurRx also announced that it... Read More »
Trulieve Cannabis Merges With Harvest Health

Trulieve Cannabis Merges With Harvest Health

The medical marijuana market just got its biggest merger. Trulieve Cannabis Corp. (OTC: TCNNF), a vertically integrated “seed-to-sale” company, announced last week the acquisition of Harvest Health & Recreation Inc. for $2.1 billion. Harvest Health is a vertically integrated medical cannabis company and multi-state operator. The company also operates retail locations.  Trulieve will acquire all Harvest Shares, with each Harvest Shareholder receiving 0.1170 of a Trulieve Share for each Harvest Share, implying a price per Harvest Share of $4.79, a 34% premium to the May 7, 2021 closing price. Harvest Health generated $231.6 million in revenue in 2020 and... Read More »
Pfizer Acquires Amplyx Pharmaceuticals

Pfizer Acquires Amplyx Pharmaceuticals

After getting its Covid-19 vaccine to market in record time, Pfizer Inc. (NYSE: PFE) is back on the acquisition trail. The pharmaceutical giant has purchased Amplyx Pharmaceuticals, Inc. for an undisclosed sum. Amplyx Pharmaceuticals is a privately-held company dedicated to the development of therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. Amplyx’s lead compound, Fosmanogepix (APX001), is a novel investigational asset under development for the treatment of invasive fungal infections.  In addition to Fosmanogepix, with this acquisition, Pfizer has secured ownership of Amplyx’s early-stage pipeline that includes potential antiviral... Read More »
Procaps Group Merges with Union Acquisition

Procaps Group Merges with Union Acquisition

If you were looking for another SPAC deal this week, say no more. Procaps Group announced a reverse merger with Union Acquisition Corp. II (NASDAQ: LATN). Founded in 1977, Procaps is a leading integrated international healthcare and pharmaceutical company with a successful history of growth and diversification. Procaps is the largest pharmaceutical integral CDMO in Latin America, and its proprietary portfolio of branded Rx and OTC products and services is sold, distributed, or provided to over 50 markets. It has six state-of-the-art manufacturing facilities in Latin America, including the first FDA-approved pharmaceutical plant in South America for selling Rx products into the United... Read More »
Jazz Pharmaceuticals Buys GW Pharmaceuticals

Jazz Pharmaceuticals Buys GW Pharmaceuticals

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is back with a new acquisition. The Ireland-based pharmaceutical company has announced the purchase of GW Pharmaceuticals plc (OTC: GWPRF) for $7.2 billion, or $220 per American Depositary Share in the form of $200 in cash and $20 in Jazz Pharmaceuticals ordinary shares. The price represents a premium of approximately 50% over GW’s closing stock price on February 2, 2021, of $146.25 and 60% over GW’s 30-day volume-weighted average price of $137.17. GW Pharmaceuticals is a global pharmaceutical company that discovers, develops, manufactures and commercializes novel, regulatory approved therapeutics from its proprietary cannabinoid product... Read More »
Servier Builds Oncology Portfolio With New Deal

Servier Builds Oncology Portfolio With New Deal

The France-based pharmaceutical company Servier is back with a new deal, adding Agios Pharmaceuticals, Inc.‘s (NASDAQ: AGIO) oncology portfolio for $1.8 billion upfront in cash. The portfolio consists of Agios’ commercial, clinical and research-stage oncology product line, which includes Tibsovo, a treatment for adults with IDH1-mutant relapsed or refractory acute myeloid leukemia, and additional oncology pipeline and clinical programs. The deal also includes Agios’ co-commercialization responsibilities for Bristol Myers Squibb’s (NYSE: BMY) IDHIFA and certain clinical development activities within the IDHIFA development program.  In addition to the upfront payment, Servier will pay Agios... Read More »